These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33782808)

  • 1. Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank.
    Zou B; Yeo YH; Cheung R; Ingelsson E; Nguyen MH
    Dig Dis Sci; 2021 Jun; 66(6):2092-2100. PubMed ID: 33782808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort.
    Sharma D; Gotlieb N; Farkouh ME; Patel K; Xu W; Bhat M
    J Am Heart Assoc; 2022 Jan; 11(1):e022576. PubMed ID: 34927450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study.
    Kim JH; Moon JS; Byun SJ; Lee JH; Kang DR; Sung KC; Kim JY; Huh JH
    Cardiovasc Diabetol; 2020 May; 19(1):51. PubMed ID: 32359355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the Dallas Steatosis Index to Predict Nonalcoholic Fatty Liver Disease in the UK Biobank Population.
    McHenry S; Park Y; Davidson NO
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2638-2640. PubMed ID: 34044131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between an inflammatory diet index and severe non-alcoholic fatty liver disease: a prospective study of 171,544 UK Biobank participants.
    Petermann-Rocha F; Wirth MD; Boonpor J; Parra-Soto S; Zhou Z; Mathers JC; Livingstone K; Forrest E; Pell JP; Ho FK; Hébert JR; Celis-Morales C
    BMC Med; 2023 Apr; 21(1):123. PubMed ID: 37013578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioural activity pattern, genetic factors, and the risk of nonalcoholic fatty liver disease: A prospective study in the UK Biobank.
    Ge X; Wang X; Yan Y; Zhang L; Yu C; Lu J; Xu X; Gao J; Liu M; Jiang T; Ke B; Song C
    Liver Int; 2023 Jun; 43(6):1287-1297. PubMed ID: 37088982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases.
    Motamed N; Rabiee B; Poustchi H; Dehestani B; Hemasi GR; Khonsari MR; Maadi M; Saeedian FS; Zamani F
    Clin Res Hepatol Gastroenterol; 2017 Feb; 41(1):31-38. PubMed ID: 27597641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diet and Risk of Non-Alcoholic Fatty Liver Disease, Cirrhosis, and Liver Cancer: A Large Prospective Cohort Study in UK Biobank.
    Guo W; Ge X; Lu J; Xu X; Gao J; Wang Q; Song C; Zhang Q; Yu C
    Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between fasting plasma glucose and nonalcoholic fatty liver disease in a nonobese Chinese population with normal blood lipid levels: a prospective cohort study.
    Zou Y; Yu M; Sheng G
    Lipids Health Dis; 2020 Jun; 19(1):145. PubMed ID: 32563249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes.
    Mantovani A; Mingolla L; Rigolon R; Pichiri I; Cavalieri V; Zoppini G; Lippi G; Bonora E; Targher G
    Int J Cardiol; 2016 Dec; 225():387-391. PubMed ID: 27768965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up.
    Fracanzani AL; Tiraboschi S; Pisano G; Consonni D; Baragetti A; Bertelli C; Norata D; Valenti L; Grigore L; Porzio M; Catapano A; Fargion S
    Atherosclerosis; 2016 Mar; 246():208-13. PubMed ID: 26803429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study.
    Allen AM; Hicks SB; Mara KC; Larson JJ; Therneau TM
    J Hepatol; 2019 Dec; 71(6):1229-1236. PubMed ID: 31470068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alcoholic and Nonalcoholic Fatty Liver Disease and Incident Hospitalization for Liver and Cardiovascular Diseases.
    Chang Y; Cho J; Cho YK; Cho A; Hong YS; Zhao D; Ahn J; Sohn CI; Shin H; Guallar E; Ryu S
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):205-215.e7. PubMed ID: 31085337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease and cardiovascular disease.
    Hyogo H; Chayama K; Yamagishi S
    Curr Pharm Des; 2014; 20(14):2403-11. PubMed ID: 23844815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex differences in the impact of nonalcoholic fatty liver disease on cardiovascular risk factors.
    Du T; Sun X; Yuan G; Zhou X; Lu H; Lin X; Yu X
    Nutr Metab Cardiovasc Dis; 2017 Jan; 27(1):63-69. PubMed ID: 27956025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between night shift work and NAFLD: a prospective analysis of 281,280 UK Biobank participants.
    Huang H; Liu Z; Xie J; Xu C
    BMC Public Health; 2023 Jul; 23(1):1282. PubMed ID: 37400787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of fatty liver index with the risk of incident cardiovascular disease and acute myocardial infarction.
    Olubamwo OO; Virtanen JK; Voutilainen A; Kauhanen J; Pihlajamäki J; Tuomainen TP
    Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1047-1054. PubMed ID: 29912803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
    Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
    Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.